Mode
Text Size
Log in / Sign up

Hepatic macrophage metabolic reprogramming and bidirectional signaling dictate the balance between liver injury and regenerationNew research identifies how liver cells communicate during chronic disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that macrophage metabolic switches and bidirectional signaling are key drivers of liver repair and inflammation.

This systematic review explores the complex role of hepatic macrophages in various chronic liver diseases, including MASLD, ALD, and viral hepatitis. The review synthesizes evidence regarding how tissue-resident macrophages and monocyte-derived macrophages differentiate into specific subsets, such as LAMs, SAMs, and SenAMs, depending on the disease environment.

Key findings highlight metabolic reprogramming as a critical mechanism. Glycolysis acts as a switch for pro-inflammatory polarization, while oxidative phosphorylation and fatty acid oxidation serve as switches for tissue-repair phenotypes. Furthermore, bidirectional signaling between macrophages and other liver cells, including hepatocytes and stellate cells, is essential for maintaining the balance between injury and regeneration. These interactions are mediated by macrophage-derived autophagy, LC3-associated phagocytosis, and exosomal cargo transfer.

The review identifies these multi-layered regulatory networks as potential targets for treating liver fibrosis and cirrhosis. However, the evidence is currently theoretical and does not provide clinical trial data. The findings suggest that targeting specific macrophage metabolic pathways or intercellular communication may offer new avenues for managing the progression of chronic liver diseases.

How this fits prior evidence

This systematic review identifies novel therapeutic targets for chronic liver diseases, including MASLD and hepatocellular carcinoma. These findings complement the evidence that Dioscin shows therapeutic potential for MASLD and hepatocellular carcinoma. While the current review focuses on the underlying cellular and metabolic mechanisms of macrophage-mediated repair, the prior coverage of Dioscin addresses a specific pharmacological intervention for these same conditions.

When the liver faces chronic issues like fatty liver disease or scarring, it relies on a complex internal communication system. A new review shows that specific immune cells, called macrophages, act as the main messengers. These cells can change their behavior depending on the type of injury the liver faces, switching between roles that promote inflammation or those that help the organ heal.

This process is driven by a shift in how these cells produce energy. For example, a switch to glycolysis fuels inflammation, while other processes like fatty acid oxidation help with tissue repair. These cells also talk to neighboring liver cells to balance out damage and regeneration. This communication happens through several pathways, including the movement of cargo between cells and internal cleaning processes.

While this research provides a detailed map of how liver cells interact, it is important to note that these findings come from a theoretical framework. The study identifies potential targets for future treatments rather than providing data from clinical trials. It highlights the complex ways the body tries to manage liver health across various conditions.

What this means for you:
Immune cells in the liver can switch between causing inflammation and repairing tissue based on internal signals.

Common questions

How do immune cells affect liver health?

Immune cells called macrophages act as messengers in the liver. They can change their behavior based on the type of injury. Some types of these cells promote inflammation, while others focus on repairing the tissue. They communicate with other liver cells to help the organ balance out damage and regeneration.

What causes these cells to switch roles?

The switch is driven by how the cells produce energy. For example, a process called glycolysis acts as a switch for inflammation. Other processes, like oxidative phosphorylation and fatty acid oxidation, act as switches for tissue repair. These metabolic changes determine whether the cell helps the liver heal or fuels inflammation.

Is this a new treatment for liver disease?

This research is not a new treatment. It is a review that identifies new targets for future medicine. It explains the complex ways liver cells communicate and how they might be targeted in the future to treat conditions like fatty liver disease or liver scarring.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Chronic liver diseases (CLDs), including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD, viral hepatitis, liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC)), impose enormous global public health burdens. Hepatic macrophages act as core orchestrators governing the initiation and progression of all CLD subtypes. This review systematically integrates recent advances regarding hepatic macrophage ontogeny, spatial heterogeneity, metabolic rewiring, multi-cellular communication, and systemic neuro-immune crosstalk along the gut-liver-brain axis. Beyond the outdated binary M1/M2 classification, tissue-resident macrophages (ResMø) and recruited monocyte-derived macrophages (MDMs) differentiate into disease-specific subsets (LAMs, SAMs, SenAMs) with spatially restricted, context-dependent functions. Metabolic reprogramming-glycolysis for pro-inflammatory polarization versus oxidative phosphorylation (OXPHOS)/fatty acid oxidation (FAO) for tissue-repair phenotypes-serves as the intrinsic molecular switch shaping macrophage effector profiles. Extrinsically, bidirectional signaling between hepatic macrophages and hepatocytes, hepatic stellate cells (HSCs), liver sinusoidal endothelial cells (LSECs), and other intrahepatic immune cells dictates the balance between hepatic injury and tissue regeneration. Macrophage-derived autophagy, LC3-associated phagocytosis (LAP), and exosomal cargo transfer represent pivotal functional executors mediating intercellular signal transmission. Furthermore, gut microbial metabolites and bidirectional liver-brain neuroimmune signals converge on hepatic macrophages, linking local hepatic inflammation to systemic metabolic and neurocognitive complications. This review further summarizes unresolved bottlenecks and translational prospects for macrophage-targeted precision therapy. Collectively, these multi-layered regulatory networks provide a comprehensive theoretical framework for identifying novel therapeutic targets across the full spectrum of CLDs.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.